Qiagen NV 最大收入来源是 Consumables and Related,在最近的收益报告中收入为 1,726,200,000。就地区而言, United States 是 Qiagen NV 的主要市场,收入为 935,281,000。
Qiagen NV 是否盈利?
是的,根据最新的财务报表,Qiagen NV 的净利润为 $424
Qiagen NV 有负债吗?
不,Qiagen NV 的负债为 0
Qiagen NV 的流通股有多少?
Qiagen NV 的总流通股为 0
360报告
关键数据
前收盘价
$39.92
开盘价
$39.99
当日区间
$39.48 - $40.35
52周范围
$38.13 - $57.82
交易量
1.5M
平均成交量
2.4M
股息收益率
--
每股收益(TTM)
2.00
市值
$8.1B
什么是 QGEN?
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,654 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.